

ASX ANNOUNCES NON-EXECUTIVE BOARD APPOINTMENTS

Acrux (ASX: ACR) today announced that Dr. Geoffrey Brooke and Dr. Simon Green have joined the Board as non-executive directors.

Dr. Brooke graduated from Melbourne University with a medical degree and initially practised as a consultant anaesthetist and physician before moving into venture capital. His career includes thirty years of investing in and advising companies on the commercialisation of medical technologies. He is the founder and former Managing Director of GBS Venture Partners, an investor in early stage businesses in biopharmaceuticals, medical devices and services. Geoff has extensive experience in all stages of biotechnology development and commercialisation, including licensing and trade sales. He has considerable board experience in the sector and remains a director of two US-based GBS portfolio companies and the local board representative of two US healthcare companies with Australian clinical operations. Geoff has a significant international network within the life sciences sector.

Dr. Green graduated with a PhD from Melbourne University and has 25 years' experience in the biotechnology industry. During a 17 year career at CSL Ltd, Simon held a variety of roles including as Senior Vice President in a number of CSL's research and development divisions. He has held various roles in CSL's Global Leadership Committees and has experience in drug development, strategic planning, portfolio management, intellectual property management and business development. Simon left CSL in 2015 to establish Immunosis Pty. Ltd., which is developing gene based diagnostics.

Acrux Chairman Ross Dobinson commented: "We are very pleased to announce these two new appointments. Both Geoff and Simon have extensive experience in drug development and commercialisation, which is relevant as Acrux moves forward with the development of its pipeline of products".

For further information, contact

Ross Dobinson, Chairman: 03 8379 0100

About Acrux

Acrux (ASX: ACR) is a drug development company focused on commercialising topical products using its proprietary drug delivery technology. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and licensed a number of pharmaceutical products in the US and Europe using the Patchless Patch™, a fast-drying and invisible topical application technology. Acrux will continue to innovate and bring its developed products to the market in collaboration with licensees.

For further information on Acrux, visit www.acrux.com.au

